HIV TREATMENT
2020
Action 27. Mobilize their networks and work with communities to help build treatment literacy, generate demand, and expand access to ARVs among children.
Action 34. Increase efforts to share information on the roll-out of new paediatric formulations, including lessons learned.
Paediatric HIV & TB : Rome Action Plan
2022 Rome Action Plan on Paediatric HIV & TB
AMF
Access to Medicine Foundation commits to include appropriate metrics to capture alignment with the Call To Action[1]principles in their next access index for pharmaceutical companies, and specifically:
23. Complete a review of how pregnant and lactating women are represented in the 2023 Access to Medicine Index Methodology and make subsequent changes to the methodology, as required to continue to reflect their unique needs by Q4 2023.
24. Highlight key opportunities for the pharmaceutical companies within the scope of its research pertaining to pregnant and lactating women as an inclusion in its collaborative engagement work aimed at moving the pharmaceutical industry further and faster on key topics by Q4 2025.
25. Explore the unique needs of pregnant and lactating women in the consultation process and the subsequent development of new frameworks for evaluation, as part of its 5-year Strategic Direction.
[1] See Annex section Rome 6 - https://www.paediatrichivactionplan.org/high-level-dialogues
-
Access to Medicine Foundation commits to:
313. Completing a review of how paediatric populations are represented in the 2023 Access to Medicine Index Methodology and to making subsequent changes to the methodology, as required to continue to reflect their unique needs by Q4 2023.
314. Highlighting key opportunities for the pharmaceutical companies within the scope of our research pertaining to paediatric populations as an inclusion in our collaborative engagement work aimed at moving the pharmaceutical industry further and faster on key topics by Q4 2025.
315. Exploring the unique needs of paediatric populations in the consultation process and the subsequent development of new frameworks for evaluation, as part of its 5-year Strategic Direction.
-
Access to Medicine Foundation commits to:
360. Complete a review of how paediatric populations and pregnant and lactating women are represented in the 2023 Access to Medicine Index Methodology and to making subsequent changes to the methodology, as required to continue to reflect their unique needs by Q4 2023.
361. Highlight key opportunities for the pharmaceutical companies within the scope of our research pertaining to paediatric populations and pregnant and lactating women as an inclusion in our collaborative engagement work aimed at moving the pharmaceutical industry further and faster on key topics by Q4 2025.
362. Explore the unique needs of paediatric populations as well as pregnant and lactating women in the consultation process and the subsequent development of new frameworks for evaluation, as part of its 5-year Strategic Direction.
-
All partners commit to:
163. Address inequities by tackling the stigma and discrimination in communities, schools, and healthcare settings that prevent children living with HIV from accessing testing and treatment.
164. Increase literacy about CD4 testing and viral load and promote a client-centred approach to support expansion of access to viral load for pregnant and breastfeeding women and children on treatment, including at the point-of-care.
165. Review and assess emerging co-infections for immunocompromised infants and children, including those with advanced HIV disease, such as severe bacterial infections, fungal infections, and others for country consideration and implementation.
166. Engage affected communities for input and guidance on investment and programmatic priorities, provide support to in-country civil society organizations to engage in advocacy and demand creation for new tools, and ensure data is publicly available to support communities and civil society to monitor progress regarding uptake and implementation of essential diagnostic tools.
-